Immune globulin - OMRIX Viopharmaceuticals

Drug Profile

Immune globulin - OMRIX Viopharmaceuticals

Alternative Names: Immune deficiency immune globulin therapy - Omrix; Immunoglobulin intravenous - Omrix; Intravenous immunoglobulin - Omrix; Omr-IgG-am; Omr-IgG-am™-IVIG

Latest Information Update: 31 Jul 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OMRIX Biopharmaceuticals
  • Class Antidementias; Antivirals; Immunoglobulins; Immunoproteins; Serum globulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Autoimmune disorders; Immunodeficiency disorders

Most Recent Events

  • 30 Dec 2008 OMRIX Biopharmaceuticals has been acquired by Johnson and Johnson
  • 28 Sep 2006 IVIG has been licensed to FFF enterprises in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top